The FDA is investigating Sarepta Therapeutics' gene therapy for Duchenne muscular dystrophy following patient deaths linked to liver failure. This regulatory scrutiny highlights concerns over safety profiles of gene therapies targeting rare genetic diseases. The investigation reflects ongoing challenges regulators face balancing innovation with patient safety in advanced therapeutics.